There is a need for new and effective antiretrovirals.

To determine the safety and efficacy of TMC-114 when used in combination with ritonavir.

 

 

This new clinical trial is a randomized, Phase II, partially-blinded 48 week study of TMC-114 in volunteers with drug resistant HIV.

Study volunteers will be randomly assigned to one of five treatment groups. Four groups receive different doses of TMC-114 along with their new genotypic based drug regimen; one group does not receive TMC-114 initially, but will receive their genotypic testing results and later may be eligible to receive study drug.

This study also includes resistance testing via the VirtualPhenotype.

 

• HIV-positive adult
• Viral load greater than 1000
• Eligibility is based on past and current drug resistance testing

Enrolling
--

This ad was reviewed and approved by the AIDS ReSearch Alliance Institutional Review Board in June, 2004.